Kenneth Gordon to Tumor Necrosis Factor-alpha
This is a "connection" page, showing publications Kenneth Gordon has written about Tumor Necrosis Factor-alpha.
Connection Strength
1.328
-
Strategies for treatment with anti-tumor necrosis factor agents in psoriasis: maintaining efficacy and safety for the long haul. Arch Dermatol. 2010 Feb; 146(2):186-8.
Score: 0.248
-
The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol. 2005 Nov; 153(5):945-53.
Score: 0.185
-
Sequencing of Targeted Therapy in Psoriasis: Does it Matter? Am J Clin Dermatol. 2024 Sep; 25(5):795-810.
Score: 0.169
-
Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. Dermatol Ther. 2004; 17(5):427-31.
Score: 0.163
-
Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2). Br J Dermatol. 2021 04; 184(4):652-662.
Score: 0.129
-
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018 08 25; 392(10148):650-661.
Score: 0.112
-
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. N Engl J Med. 2015 Jul 09; 373(2):136-44.
Score: 0.090
-
Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. J Dermatol Sci. 2007 Nov; 48(2):87-101.
Score: 0.052
-
The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach. J Am Acad Dermatol. 2006 Mar; 54(3 Suppl 2):S85-91.
Score: 0.047
-
Unmet needs in the treatment of psoriasis. Eur J Dermatol. 2014 Sep-Oct; 24(5):523-32.
Score: 0.021
-
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011 Aug 24; 306(8):864-71.
Score: 0.017
-
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008 May; 58(5):826-50.
Score: 0.014
-
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008 May; 58(5):851-64.
Score: 0.014
-
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008 Jan; 58(1):106-15.
Score: 0.013
-
Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007 Jun; 143(6):719-26.
Score: 0.013
-
Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat. 2007; 18(6):341-50.
Score: 0.013
-
Lessons learned from psoriatic plaques concerning mechanisms of tissue repair, remodeling, and inflammation. J Investig Dermatol Symp Proc. 2006 Sep; 11(1):16-29.
Score: 0.012
-
Differential abilities of central nervous system resident endothelial cells and astrocytes to serve as inducible antigen-presenting cells. Blood. 2002 May 15; 99(10):3692-701.
Score: 0.009
-
In vivo gene therapy with interleukin-12 inhibits primary vascular tumor growth and induces apoptosis in a mouse model. J Invest Dermatol. 1999 May; 112(5):775-81.
Score: 0.007